Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. director Steve E. Krognes exercised restricted stock units into common stock in a routine compensation-related transaction. On April 30, 2026, 154 common shares were acquired upon RSU vesting, bringing his direct common stock holdings to 19,362 shares.
The RSUs originated from an award granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over three years. After this vesting event, he holds 309 restricted stock units directly.
Vanguard Capital Management reported holding 6,589,394 shares of Guardant Health common stock, representing 5.02% of the class as of 03/31/2026. The filing shows sole dispositive power over 6,589,394 shares and sole voting power over 965,214 shares. The Schedule 13G form is signed by Ashley Grim as Head of Global Fund Administration on 04/30/2026.
Guardant Health is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026, where they will elect two Class II directors, ratify Deloitte as auditor, and hold advisory votes on executive pay and the frequency of future pay votes.
The proxy highlights a strong 2025, with 363,000 clinical tests and $982 million in revenue, representing 33% year-over-year growth. Screening advanced with about 87,000 Shield tests, generating roughly $80 million and securing a $1,495 Medicare rate and guideline inclusion. The Board reports 9 of 11 directors as independent, increasing its focus on governance, ESG reporting and pay-for-performance programs that tie bonuses and performance share units to revenue growth, adjusted EBITDA and long-term shareholder returns.
Guardant Health, Inc. disclosed that its Chief Medical Officer, Craig Eagle, M.D., has resigned. His resignation is scheduled to take effect on May 8, 2026. The company reported this leadership change in a current report signed by its Chief Legal Officer and Corporate Secretary, John G. Saia.
Guardant Health, Inc. director Roberto Mignone acquired 264 common shares through RSU vesting. On April 21, 2026, 264 Restricted Stock Units converted into 264 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase or sale.
Following the transaction, Mignone directly holds 4,751 shares of common stock and 7,920 Restricted Stock Units. The RSUs come from an award granted on November 8, 2024 that vests over four years. According to the award terms, 25% of the RSUs vested on October 21, 2025, and the remaining 75% vests in equal monthly installments over the next three years.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares. On April 17, 2026, he acquired 232 shares of Guardant Health, Inc. common stock through a derivative exercise at a stated price of $0.00 per share.
Following the transaction, he directly holds 1,657 shares of common stock and 6,265 restricted stock units. The RSU award, granted on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health director Tariq Musa reported routine equity activity tied to a prior restricted stock unit (RSU) grant. On April 15, 2026, he exercised 250 Restricted Stock Units at $0.00, converting them into 250 shares of Common Stock. On April 16, 2026, he completed an open-market sale of 116 Common Stock shares at an average price of $84.83 per share.
Following these transactions, Musa directly holds 8,528 shares of Common Stock and 2,749 Restricted Stock Units. The RSU award, granted on March 6, 2023, vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over the next three years.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 15, 2026, 7,569 restricted stock units converted into an equal number of Guardant Health common shares at no exercise price as part of a scheduled vesting.
Of these vested shares, 3,970 were retained by the company to satisfy Mr. Saia’s tax withholding obligations at a reference price of $84.86 per share, which is a tax-withholding disposition rather than an open-market sale. After these transactions, he directly owns 65,950 shares of Guardant Health common stock.
Guardant Health reported a Form 144 notice relating to the proposed sale of Common stock. The filing lists 9,840 Common shares with a filing date of 04/16/2026 via Charles Schwab. The excerpt also notes a restricted stock lapse on 02/15/2026 and a reported sale of 348 shares by Musa Tariq on 03/18/2026.